Literature DB >> 6896123

Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25-dihydroxycholecalciferol concentrations.

M J Prince, P C Schaeffer, R S Goldsmith, A B Chausmer.   

Abstract

Seven siblings with hyperphosphatemic tumoral calcinosis were studied using metabolic measures. Serum phosphorus and 1, 25-dihydroxycholecalciferol concentrations were significantly increased and serum parathyroid hormone and 25-hydroxycholecalciferol concentrations were significantly decreased in these subjects. Metabolic balance studies done in three of the siblings showed positive calcium and phosphorus balances, reflected by increased gastrointestinal absorption and decreased renal excretion. These data suggest that a hereditary abnormality of vitamin D metabolism may be present in patients with hyperphosphatemic tumoral calcinosis. Failure of the normal feedback mechanism regulating the 25-hydroxy-1-alpha-hydroxylase enzyme is suggested as the major cause. Although this defect could lead to many of the metabolic abnormalities seen in these patients, the overall contribution of altered vitamin D metabolism to the pathogenesis of tumoral calcinosis is not fully understood.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896123     DOI: 10.7326/0003-4819-96-5-586

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  23 in total

1.  A report of familial hyperphosphataemia in an Irish family.

Authors:  S W Li Voon Chong; S Ah Kion; M J Cullen
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

2.  An ocular presentation of familial tumoral calcinosis.

Authors:  Emer McGrath; Fiona Harney; Frank Kinsella
Journal:  BMJ Case Rep       Date:  2010-09-20

3.  A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.

Authors:  Ilana Chefetz; Raoul Heller; Assimina Galli-Tsinopoulou; Gabriele Richard; Bernd Wollnik; Margarita Indelman; Friederike Koerber; Orit Topaz; Reuven Bergman; Eli Sprecher; Eckhard Schoenau
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

Review 4.  Vitamin D-endocrine system.

Authors:  N H Bell
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

5.  Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis.

Authors:  R Candrina; B Cerudelli; V Braga; A Salvi
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

6.  Vitamin D metabolism in tumoral calcinosis.

Authors:  R Steinherz
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

Review 7.  Clinical disorders of phosphorus metabolism.

Authors:  G C Yu; D B Lee
Journal:  West J Med       Date:  1987-11

8.  Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.

Authors:  Leo Joseph; Sandra N Hing; Nadege Presneau; Paul O'Donnell; Tim Diss; Bernadine D Idowu; Selvanayagam Joseph; Adrienne Margaret Flanagan; David Delaney
Journal:  Skeletal Radiol       Date:  2009-10-15       Impact factor: 2.199

9.  Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.

Authors:  Eli Sprecher
Journal:  J Invest Dermatol       Date:  2009-10-29       Impact factor: 8.551

10.  Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis.

Authors:  Holly J Garringer; Mahdi Malekpour; Fatemehsadat Esteghamat; Seyed M J Mortazavi; Siobhan I Davis; Emily G Farrow; Xijie Yu; Dan E Arking; Harry C Dietz; Kenneth E White
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-08-05       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.